Abstract: A composition comprising, in a physiologically acceptable medium, a crosslinked hyaluronic acid (HA), having a degree of modification less than 1.9 mole %; a HA with a molecular weight of about 50 kDa or less; and/or an agent stimulating endogenous HA synthesis. Also disclosed is a cosmetic use of such composition in skin care and/or anti-ageing treatment.

Abstract: A composition is described that includes lipid microcapsules and at least one dispersed active principle. A method is also described for preparing the composition. Also described, is the use of the composition in the treatment of dermatological diseases.

Abstract: A process is described for preparing a stable emulsion that includes at least one avermectin. Also described, is the emulsion thus obtained, especially for use in the treatment of dermatological disorders such as rosacea.

Abstract: The invention relates to a composition in the form of a water-in-oil (W/O) emulsion suitable for topical administration.

Abstract: A micro- or nanoparticular vesicle comprises at least a crosslinked hyaluronic acid (HA), wherein the crosslinked hyaluronic acid is crosslinked by a chemical crosslinking agent, and wherein the degree of modification of said crosslinked hyaluronic acid with said chemical crosslinking agent is less than 1.9 mole %. Also disclosed are a method of manufacturing such vesicles, compositions comprising such vesicles and their uses.

Abstract: Stable cream gel dermatological/cosmetic compositions useful, e.g., for the treatment of acne vulgaris, contain, formulated into a physiologically acceptable medium, a homogeneous dispersion of at least one dispersed retinoid, dispersed benzoyl peroxide, at least one lipophilic compound and at least one gelling agent.

Abstract: A composition or nanosuspension is described that includes water dispersible nanoparticles of a retinoid compound having an average particle size of less than about 500 nm. Also described, are pharmaceutical compositions intended for topical administration, including such a composition or nanosuspension. Uses of such pharmaceutical compositions in the treatment of skin diseases, particularly acne, ichthyosis and psoriasis are also described.

Abstract: Lipid microcapsules are described that can include at least one lipophilic active substance, more specifically a retinoid, in a soluble form. Also described, are pharmaceutical compositions including the same and a method for the production thereof. Methods of using such a composition to treat dermatological pathologies are also described.

Abstract: A process is described for preparing a composition in the form of an emulsion that includes a high concentration of one or more avermectins. This process can include partitioning the avermectin between an active phase, including at least one glycol, and an oily phase of the emulsion. A composition thus obtained, is also described that can be used in the treatment of dermatological disorders such as rosacea.

Abstract: Lipid microcapsules are described that can include at least one irritant active substance, more specifically a retinoid, in a soluble form. Also described, are pharmaceutical compositions comprising the same, and methods for the production thereof. A method of using the composition to treat dermatological pathologies is also described.

Abstract: Composition comprising avermectin compounds without solid fatty substances The invention relates to a dermatological or pharmaceutical composition comprising at least one aqueous phase and at least one active phase comprising at least one active compound chosen from avermectin compounds and at least one solvent and/or propenetrating agent of avermectin compounds, where the composition comprises less than 3% by weight of solid fatty substances at room temperature and at atmospheric pressure, relative to the total weight of the composition. The invention relates also to the composition for use in the treatment of rosacea, of common acne, of seborrheic dermatitis, of perioral dermatitis, of acneiform rashes, of transient acantholytic dermatosis, of acne necrotica miliaris and of atopic dermatitis, and preferably for use in the treatment of rosacea. Finally, the invention relates to a method for preparing the composition.

Abstract: Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds The invention relates to a dermatological or pharmaceutical composition comprising at least one aqueous phase and at least one fatty phase comprising one or more fatty compounds different from solvents and/or propenetrating agents of avermectin compounds and a least one active compound chosen from avermectin compounds, where the composition comprises neither solvents nor propenetrating agents of avermectin compounds. The invention relates also to the composition for use in the treatment of rosacea, of common acne, of seborrheic dermatitis, of perioral dermatitis, of acneiform rashes, of transient acantholytic dermatosis, of acne necrotica miliaris and of atopic dermatitis, and preferably for use in the treatment of rosacea. Finally, the invention relates to a method for preparing the composition.

Abstract: Lipid nanocapsules are described that include at least one irritating active ingredient, and more specifically a retinoid in solubilized form. Also described, are nanodispersions and pharmaceutical compositions including the same and methods of producing the same. The use of the pharmaceutical compositions in the treatment of dermatological pathologies is also described.

Abstract: Stable dermatological/cosmetic emulsions useful, e.g., for the treatment of acne vulgaris, contain, formulated into a physiologically acceptable medium, a homogeneous dispersion of at least one dispersed retinoid, dispersed benzoyl peroxide, at least one fatty phase, at least one hydrophilic phase and at least one emulsifier.

Abstract: The invention relates to a dermatological or pharmaceutical composition comprising at least one aqueous phase, at least one fatty phase comprising one or more fatty compounds and at least one active phase comprising one or more active compounds chosen from avermectin compounds and one or more solvents and/or propenetrating agents of avermectin compounds, where the composition does not comprise gelling agent. The invention relates also to the composition for use in the treatment of rosacea, of common acne, of seborrheic dermatitis, of perioral dermatitis, of acneiform rashes, of transient acantholytic dermatosis, of acne necrotica miliaris and of atopic dermatitis, and preferably for use in the treatment of rosacea. Finally, the invention relates to a method for preparing the composition.

Abstract: A micro- or nanoparticular multilamellar vesicle is constituted of concentric membranes comprising at least one non-ionic surfactant of the sucrose ester type comprising at least one chain arising from a linear or branched, saturated or unsaturated, optionally mono- or polyhydroxylated C12 to C22 fatty acid, which vesicle comprises at least a hyaluronic acid (HA), wherein the hyaluronic acid is a crosslinked hyaluronic acid. Also disclosed are a method of manufacture of such vesicle, compositions comprising such vesicle and their uses.

Abstract: A micro- or nanoparticular vesicle comprises at least a crosslinked hyaluronic acid (HA), wherein the crosslinked hyaluronic acid is crosslinked by a chemical crosslinking agent, and wherein the degree of modification of said crosslinked hyaluronic acid with said chemical crosslinking agent is less than 1.9 mole %. Also disclosed are a method of manufacturing such vesicles, compositions comprising such vesicles and their uses.

Abstract: A composition comprising, in a physiologically acceptable medium, a crosslinked hyaluronic acid (HA), having a degree of modification less than 1.9 mole %; a HA with a molecular weight of about 50 kDa or less; and/or an agent stimulating endogenous HA synthesis. Also disclosed is a cosmetic use of such composition in skin care and/or anti-ageing treatment.

Abstract: The invention relates to a dermatological or pharmaceutical composition comprising at least one aqueous phase, at least one fatty phase comprising one or more fatty compounds and at least one active phase comprising one or more active compounds chosen from avermectin compounds and one or more solvents and/or propenetrating agents of avermectin compounds, where the composition does not comprise gelling agent. The invention relates also to the composition for use in the treatment of rosacea, of common acne, of seborrheic dermatitis, of perioral dermatitis, of acneiform rashes, of transient acantholytic dermatosis, of acne necrotica miliaris and of atopic dermatitis, and preferably for use in the treatment of rosacea. Finally, the invention relates to a method for preparing the composition.

Abstract: The invention relates to a dermatological or pharmaceutical composition comprising at least one aqueous phase and at least one active phase comprising at least one active compound chosen from avermectin compounds and at least one solvent and/or propenetrating agent of avermectin compounds, where the composition comprises less than 3% by weight of solid fatty substances at room temperature and at atmospheric pressure, relative to the total weight of the composition. The invention relates also to the composition for use in the treatment of rosacea, of common acne, of seborrheic dermatitis, of perioral dermatitis, of acneiform rashes, of transient acantholytic dermatosis, of acne necrotica miliaris and of atopic dermatitis, and preferably for use in the treatment of rosacea. Finally, the invention relates to a method for preparing the composition.